



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

: Patent Term Extension Application  
Filed : March 6, 1997  
For : USPN 5,171,569; Issued: December 15, 1992  
For : FACTOR IX PREPARATIONS UNCONTAMINATED BY  
PLASMA COMPONENTS OR POX VIRUS

GP 7814  
1652  
7/764013

MAR 12 1999  
4300  
GROUP 12  
#44  
8-7-00  
02

March 3, 1999

VIA FACSIMILE  
(703) 308-6916  
ATTN: Hiram H. Bernstein  
Senior Legal Advisor  
Special Program Law Office  
Office of the Deputy Assistant Commissioner  
for Patent Policy and Projects  
Assistant Secretary and Honorable  
Commissioner of Patents and Trademarks  
Box Patent Ext.  
Washington, DC 20231

Certificate of Facsimile Transmission	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
Steven R. Lazar	
Type or print name of person signing certificate.	
Signature	3/3/99
	Date

STATUS INQUIRY

We are in receipt of a letter, dated July 24, 1998, from the United States Food and Drug Administration to the United States Patent and Trademark Office, which advises that the FDA has determined that BeneFIX [recombinant human Factor IX protein] is a product which was subject to a regulatory review period, and is therefore eligible for patent term extension. However, we have not seen publication of a notice in the Federal Register of such determination, nor have we received any further communication from either the FDA or the PTO.

The Applicants respectfully request information regarding the status of the present application for patent term extension. The Advisor is invited to contact the attorney listed below.

Respectfully submitted,

Steven R. Lazar  
Reg. No. 32,618  
Attorney for Applicants  
(617) 498-8260

Genetics Institute, Inc.  
87 CambridgePark Drive  
Cambridge, MA 02140